Mimicry of CD40 Signals by Epstein-Barr Virus LMP1 in B Lymphocyte Responses
10.1126/science.286.5438.300
Crossref journal-article
American Association for the Advancement of Science (AAAS)
Science (221)
Abstract

The effect of the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) on the activation and differentiation of normal B cells was investigated. B cells of transgenic mice expressing LMP1 under the control of immunoglobulin promoter/enhancer displayed enhanced expression of activation antigens and spontaneously proliferated and produced antibody. Humoral immune responses of LMP1 transgenic mice in CD40-deficient or normal backgrounds revealed that LMP1 mimics CD40 signals to induce extrafollicular B cell differentiation but, unlike CD40, blocks germinal center formation. Thus, these specific properties of LMP1 may determine the site of primary B cell infection and the state of infection in the natural course of EBV infection, whereas subsequent loss of LMP1 expression may affect the site of persistent latent infection.

Bibliography

Uchida, J., Yasui, T., Takaoka-Shichijo, Y., Muraoka, M., Kulwichit, W., Raab-Traub, N., & Kikutani, H. (1999). Mimicry of CD40 Signals by Epstein-Barr Virus LMP1 in B Lymphocyte Responses. Science, 286(5438), 300–303.

Authors 7
  1. Junji Uchida (first)
  2. Teruhito Yasui (additional)
  3. Yuko Takaoka-Shichijo (additional)
  4. Masaaki Muraoka (additional)
  5. Wanla Kulwichit (additional)
  6. Nancy Raab-Traub (additional)
  7. Hitoshi Kikutani (additional)
References 65 Referenced 338
  1. A. B. Rickinson and E. Kieff in Fields Virology B. N. Fields et al. Eds. (Lippincott-Raven New York ed. 3 1996) pp. 2397–2446.
  2. Aman P., Lewin N., Nordstrom M., Klein G., Curr. Top. Microbiol. Immunol. 132, 266 (1986); / Curr. Top. Microbiol. Immunol. by Aman P. (1986)
  3. Hurley E. A., Thorley-Lawson D. A., J. Exp. Med. 168, 2059 (1988); (10.1084/jem.168.6.2059) / J. Exp. Med. by Hurley E. A. (1988)
  4. Jabara H. H., et al., J. Immunol. 145, 3468 (1990); (10.4049/jimmunol.145.10.3468) / J. Immunol. by Jabara H. H. (1990)
  5. Banchereau J., de Paoli P., Valle A., Garcia E., Rousset F., Science 251, 70 (1991); (10.1126/science.1702555) / Science by Banchereau J. (1991)
  6. Gauchat J. F., Gascan H., de Waal Malefyt R., de Vries J. E., J. Immunol. 148, 2291 (1992). (10.4049/jimmunol.148.7.2291) / J. Immunol. by Gauchat J. F. (1992)
  7. Wang D., Liebowitz D., Kieff E., Cell 43, 831 (1985); (10.1016/0092-8674(85)90256-9) / Cell by Wang D. (1985)
  8. Kaye K. M., Izumi K. M., Kieff E., Proc. Natl. Acad. Sci. U.S.A. 90, 9150 (1993). (10.1073/pnas.90.19.9150) / Proc. Natl. Acad. Sci. U.S.A. by Kaye K. M. (1993)
  9. Liebowitz D., Wang D., Kieff E., J. Virol. 58, 233 (1986); (10.1128/jvi.58.1.233-237.1986) / J. Virol. by Liebowitz D. (1986)
  10. Liebowitz D., Kopan R., Fuchs E., Sample J., Kieff E., Mol. Cell. Biol. 7, 2299 (1987); / Mol. Cell. Biol. by Liebowitz D. (1987)
  11. Liebowitz D., Mannick J., Takada K., Kieff E., J. Virol. 66, 4612 (1992). (10.1128/jvi.66.7.4612-4616.1992) / J. Virol. by Liebowitz D. (1992)
  12. H. M. Hu K. O'Rourke
  13. Boguski M. S., Dixit V. M., J. Biol. Chem. 269, 30069 (1994); (10.1016/S0021-9258(18)43772-6) / J. Biol. Chem. by Boguski M. S. (1994)
  14. Rothe M., Wong S. C., Henzel W. J., Goeddel D. V., Cell 78, 681 (1994) ; (10.1016/0092-8674(94)90532-0) / Cell by Rothe M. (1994)
  15. Mosialos G. et al. 80 389 (1995); (10.1016/0092-8674(95)90489-1)
  16. Sato T., Irie S., Reed J. C., FEBS Lett. 358, 113 (1995); (10.1016/0014-5793(94)01406-Q) / FEBS Lett. by Sato T. (1995)
  17. 10.1126/science.7533327
  18. Devergne O., et al., Mol. Cell. Biol. 16, 7098 (1996); (10.1128/MCB.16.12.7098) / Mol. Cell. Biol. by Devergne O. (1996)
  19. Ishida T. K., et al., Proc. Natl. Acad. Sci. U.S.A. 93, 9437 (1996); (10.1073/pnas.93.18.9437) / Proc. Natl. Acad. Sci. U.S.A. by Ishida T. K. (1996)
  20. Sandberg M., Hammerschmidt W., Sugden B., J. Virol. 71, 4649 (1997). (10.1128/jvi.71.6.4649-4656.1997) / J. Virol. by Sandberg M. (1997)
  21. Ishida T., et al., J. Biol. Chem. 271, 28745 (1996). (10.1074/jbc.271.46.28745) / J. Biol. Chem. by Ishida T. (1996)
  22. Kulwichit W., et al., Proc. Natl. Acad. Sci. U.S.A. 95, 11963 (1998). (10.1073/pnas.95.20.11963) / Proc. Natl. Acad. Sci. U.S.A. by Kulwichit W. (1998)
  23. 10.1016/1074-7613(94)90095-7
  24. LMP1tg mice and CD40-deficient mice were produced as described (7 8). CD40-deficient LMP1tg (CD40 −/− LMP1tg) mice were established by crossing CD40 −/− mice with LMP1tg mice. The mice we used were all in the background of C57BL/6 and were heterozygous for the transgene. The targeted gene or transgene was identified by polymerase chain reaction of tail DNA. All the mice were maintained in the specific pathogen–free animal facility in accordance with the Osaka University guidelines for animal experimentation.
  25. Single-cell suspension was prepared from spleen (by lysing red blood cells with hypotonic buffer) and from bone marrow. Macrophages were prepared from the peritoneum. Splenic dendritic cells were purified as described [
  26. Metlay J. P., et al., J. Exp. Med. 171, 1753 (1990); (10.1084/jem.171.5.1753) / J. Exp. Med. by Metlay J. P. (1990)
  27. ]. For LMP1 staining cells were fixed with methanol on slide glass and stained by fluorescein isothiocyanate (FITC)–conjugated anti-Thy1.2 (30H12) FITC–anti-B220 (RA3-6B2) FITC–anti-CD11b (Mac-1) or FITC–anti-CD11c (HL3) with biotinylated anti-LMP1 (S-12) followed by Alexa 594–conjugated streptavidin (Molecular Probes). For fluorescence-activated cell sorting analysis cells were stained with biotinylated anti-CD23 (B3B4) anti-CD95 (Jo2) anti-CD54 (3E2) anti-CD80 (16-10A1) anti-CD86 (GL1) anti–I-A (17/227) or anti-IgD and FITC-conjugated anti-B220 (RA3-6B2) or anti-IgM (R6-60.2) followed by streptavidin-allophycocyanin (Becton-Dickinson). Antibodies were purchased from Pharmingen except for anti-IgD (Nordic Immunology) anti-LMP1 (provided by E. Kieff) and anti–I-A (provided by M. Kimoto). Flow cytometry was performed on a Facscalibur with Cellquest software (Becton-Dickinson).
  28. J. Uchida T. Yasui H. Kikutani unpublished data.
  29. Nonadherent splenic B cells were isolated with combination of anti-Thy1.2/CD90 (F7D5 Serotec) and complement. The remaining B cells were further fractionated through percoll gradient to purify high-density B cells yielding >95% pure B220 + B cells. Purified B cells (10 5 cells per well) were cultured in triplicate in 200 μl of RPMI medium containing 10% heat-inactivated fetal bovine serum penicillin (100 U/ml) streptomycin (100 μg/ml) 2 mM l -glutamine and 50 μM 2-mercaptoethanol in a 96-well plate. Stimulation of B cells was performed with either 5 × 10 4 cells of irradiated CD40L-expressing CHO cells (provided by H. Yagita) or murine recombinant IL-4 (Genzyme) at 100 U/ml (or both). For proliferation assay cultures were incubated for 72 hours and [ 3 H]thymidine (1 μCi per well) was added 16 hours before termination of culture. For antibody secretion assay cells were incubated for 7 days. Amounts of Igs in the culture supernatants were measured by enzyme-linked immunosorbent assay (ELISA) with the sandwich method. For detection of NF-κB activation 2 × 10 6 high-density B cells from each mouse spleen were stimulated with medium alone or with antibody to mouse CD40 (Pharmingen) or LPS (10 μg/ml each) at 37°C for 30 min. Nuclear extracts from stimulated B cells were prepared as described [
  30. Schreiber E., Matthias P., Muller M. M., Schaffner W., EMBO J. 7, 4221 (1988); (10.1002/j.1460-2075.1988.tb03319.x) / EMBO J. by Schreiber E. (1988)
  31. ]. An end-labeled self-complementary oligonucleotide containing the NF-κB site of the mouse H-2K gene was used as a probe for electrophoretic mobility shift assay [
  32. Fujita T., Nolan G. P., Ghosh S., Baltimore D., Genes Dev. 6, 775 (1992); (10.1101/gad.6.5.775) / Genes Dev. by Fujita T. (1992)
  33. ]. Nuclear extract (2.5 μg) was incubated in a buffer containing 25 mM Hepes (pH 8.9) 50 mM KCl 1 mM EDTA 1mM dithiothreitol 10% glycerol 2.5 μg of poly(deoxyinosine-deoxycytidine) and labeled probe (10 4 cpm) at 30°C for 30 min. Samples were applied to a 5% polyacrylamide gel and fractionated followed by visualization with autoradiography.
  34. Hammarskjold M. L., Simurda M. C., J. Virol. 66, 6496 (1992); (10.1128/jvi.66.11.6496-6501.1992) / J. Virol. by Hammarskjold M. L. (1992)
  35. Laherty C. D., Hu H. M., Opiari A. W., Wang F., Dixit V. M., J. Biol. Chem. 264, 24157 (1992); (10.1016/S0021-9258(18)35741-7) / J. Biol. Chem. by Laherty C. D. (1992)
  36. Rowe M., et al., J. Virol. 68, 5602 (1994) . (10.1128/jvi.68.9.5602-5612.1994) / J. Virol. by Rowe M. (1994)
  37. Castigli E., et al., Proc. Natl. Acad. Sci. U.S.A. 91, 12135 (1994); (10.1073/pnas.91.25.12135) / Proc. Natl. Acad. Sci. U.S.A. by Castigli E. (1994)
  38. 10.1084/jem.180.5.1889
  39. 10.1016/1074-7613(94)90073-6
  40. Mice were immunized intraperitoneally with 100 μg of NP 33 -CGG as an alum-precipitated complex. Total NP-specific isotype antibodies and high-affinity NP-specific IgG1 in the sera at day 14 were measured by ELISA. For detection of NP-specific IgG1 both high-affinity antibodies and total (high- plus low-affinity) antibodies were quantified by means of plates coated with NP 2 and NP 12 -conjugated BSA respectively. Bound antibodies were detected with either alkaline phosphatase–conjugated goat antibody to mouse IgM or goat antibody to mouse IgG1 (Southern Biotechnology Associates Birmingham AL).
  41. Gray D., Immunology 65, 73 (1988); / Immunology by Gray D. (1988)
  42. Jacob J., Kelsoe G., J. Exp. Med. 176, 679 (1992). (10.1084/jem.176.3.679) / J. Exp. Med. by Jacob J. (1992)
  43. Cumano A., Rajewsky K., Eur. J. Immunol. 15, 512 (1985); (10.1002/eji.1830150517) / Eur. J. Immunol. by Cumano A. (1985)
  44. 10.1084/jem.173.5.1165
  45. Spleens from mice immunized with NP 33 -CGG were isolated at the indicated period and were embedded. Frozen sections 6 μm thick were prepared with a cryostat. For the detection of GCs sections were doubly stained with antibody to mouse IgM (R6-60.2) conjugated with FITC (Pharmingen) and biotinylated PNA (Honen). For PALS-associated B cell foci sections were stained with biotinylated anti-IgG1 (A85-1 Pharmingen) and FITC–anti-λ (Southern Biotechnology Associates). Biotin-conjugated antibodies were developed with streptavidin-conjugated Texas Red (Gibco BRL).
  46. 10.1038/382462a0
  47. Kato J., et al., J. Immunol. 160, 4788 (1998); (10.4049/jimmunol.160.10.4788) / J. Immunol. by Kato J. (1998)
  48. Futtere A., Mink K., Luz A., Kosco-Vilbois M. H., Pfeffer K., Immunity 9, 59 (1998). (10.1016/S1074-7613(00)80588-9) / Immunity by Futtere A. (1998)
  49. Niedobitek G., et al., Blood 79, 2520 (1992). (10.1182/blood.V79.10.2520.bloodjournal79102520) / Blood by Niedobitek G. (1992)
  50. Robinson J. E., Smith D., Niederman J., J. Exp. Med. 153, 235 (1981); (10.1084/jem.153.2.235) / J. Exp. Med. by Robinson J. E. (1981)
  51. Anagnostopoulos I., Hummel M., Kreschel C., Stein H., Blood 85, 744 (1995). (10.1182/blood.V85.3.744.bloodjournal853744) / Blood by Anagnostopoulos I. (1995)
  52. Babcock G. J., Decker L. L., Volk M., Thorley-Lawson D. A., Immunity 9, 395 (1998). (10.1016/S1074-7613(00)80622-6) / Immunity by Babcock G. J. (1998)
  53. MacLennan I. C., Liu Y. L., Ling N. R., Curr. Top. Microbiol. Immunol. 141, 138 (1988). / Curr. Top. Microbiol. Immunol. by MacLennan I. C. (1988)
  54. Cohen J. I., Wang F., Kieff E., J. Virol. 65, 2545 (1991). (10.1128/jvi.65.5.2545-2554.1991) / J. Virol. by Cohen J. I. (1991)
  55. Miyashita E. M., Yang B., Lam K. M., Crawford D. H., Thorley-Lawson D. A., Cell 80, 593 (1995). (10.1016/0092-8674(95)90513-8) / Cell by Miyashita E. M. (1995)
  56. Hanissian S. H., Geha R. S., Immunity 6, 379 (1997); (10.1016/S1074-7613(00)80281-2) / Immunity by Hanissian S. H. (1997)
  57. Gires O., et al., EMBO J. 18, 3064 (1999). (10.1093/emboj/18.11.3064) / EMBO J. by Gires O. (1999)
  58. Hsu H., Xiong J., Goeddel D. V., Cell 81, 495 (1995); (10.1016/0092-8674(95)90070-5) / Cell by Hsu H. (1995)
  59. Izumi K. M., Kieff E. D., Proc. Natl. Acad. Sci. U.S.A. 94, 12592 (1997); (10.1073/pnas.94.23.12592) / Proc. Natl. Acad. Sci. U.S.A. by Izumi K. M. (1997)
  60. Eliopoulos A. G., Blake S. M., Floettmann J. E., Rowe M., Young L. S., J. Virol. 73, 1023 (1999) . (10.1128/JVI.73.2.1023-1035.1999) / J. Virol. by Eliopoulos A. G. (1999)
  61. Martin J., Sugden B., Cell Growth Differ. 2, 653 (1991). / Cell Growth Differ. by Martin J. (1991)
  62. 10.1126/science.276.5312.589
  63. Ye B. H., et al., Nature Genet. 16, 161 (1997); (10.1038/ng0697-161) / Nature Genet. by Ye B. H. (1997)
  64. Cattoretti G., et al., Blood 90, 175 (1997). / Blood by Cattoretti G. (1997)
  65. We thank K. Kubota for excellent secretarial assistance E. Kieff for anti-LMP1 M. Kimoto for anti–I-A and H. Yagita for CD4OL-expressing CHO cells. Supported by grants-in-aid from the Ministry of Education Science and Culture Japan (H.K.) and NIH grant CA19014 (N.R.-T.)
Dates
Type When
Created 23 years, 1 month ago (July 27, 2002, 5:45 a.m.)
Deposited 1 year, 7 months ago (Jan. 13, 2024, 5:30 a.m.)
Indexed 1 week, 1 day ago (Aug. 27, 2025, 12:37 p.m.)
Issued 25 years, 10 months ago (Oct. 8, 1999)
Published 25 years, 10 months ago (Oct. 8, 1999)
Published Print 25 years, 10 months ago (Oct. 8, 1999)
Funders 0

None

@article{Uchida_1999, title={Mimicry of CD40 Signals by Epstein-Barr Virus LMP1 in B Lymphocyte Responses}, volume={286}, ISSN={1095-9203}, url={http://dx.doi.org/10.1126/science.286.5438.300}, DOI={10.1126/science.286.5438.300}, number={5438}, journal={Science}, publisher={American Association for the Advancement of Science (AAAS)}, author={Uchida, Junji and Yasui, Teruhito and Takaoka-Shichijo, Yuko and Muraoka, Masaaki and Kulwichit, Wanla and Raab-Traub, Nancy and Kikutani, Hitoshi}, year={1999}, month=oct, pages={300–303} }